Sevuparin and sepsis
Sevuparin, a novel polysaccharide, acts by interfering with the harmful agents1 generated by white blood cells during systemic inflammation. This interference can break the molecular chain of events that lead to vascular damage and plasma leakage in patients with sepsis/septic shock and other conditions where systemic inflammation is involved.
Sevuparin directly binds and neutralizes agents released from damaged white blood cells that are known to threaten vascular integrity. This activity has been shown in pre-clinical animal models, where sevuparin has been effective in protecting the blood vessels and the lungs of mice.
At a leading intensive care congress in October 2023, final results from a Phase 1b LPS challenge study in healthy volunteers were communicated which evaluated the potential of sevuparin as a new treatment against systemic inflammations such as sepsis and endotoxemia. The study was randomized, double-blind and placebo-controlled and evaluated three different doses of sevuparin compared to placebo under induced systemic and local inflammatory conditions. The results showed an immunomodulatory potential as sevuparin significantly counteracted the decreased levels of certain white blood cells. In addition, sevuparin dose-dependently inhibited the increased respiratory rate caused by LPS, which is similar to the respiratory effects often seen in sepsis patients.